Histone deacetylase (HDAC) inhibitors are an emerging new class of anti-cancer agents with the potential for disruption of many critical cellular processes in cancer cells. One such inhibitor, FK228 (depsipeptide) was granted Fast Track designation by the Food and Drug Administration as monotherapy for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have relapsed following, or become refractory to some form of systemic therapy.
Go to Previous Page
Go to Next Page